TrialBreast cancer research and treatment2013

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer.

Massimo Cristofanilli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.